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Introduction
There are 1.5 million Americans with type 1 diabetes mellitus 
(T1DM),1 wherein severe insulin deficiency is caused by >95% 
reduction in β-cell mass.2,3 Insulin replacement remains stan-
dard therapy but does not restore normal glucose homeostasis. 
Therefore, a major goal in T1DM is restoration of β-cell mass. 
Two main pathways have been proposed for expansion of β-cell 
mass—regeneration of existing β cells or β cell neogenesis.4-7 
Recent studies8,9 showed that cell cycle regulators (cyclinD1/
D2) are essential for normal adult β cell and islet growth. Beta-
cell proliferation has been induced in isolated islets by adeno-
viral gene transfer of cyclinD2/CDK4 or cyclinD1/CDK6.10,11 
Cell cycle regulation is an integral mechanism for maintaining 
postnatal β-cell mass.12,13 Unfortunately, β cell replication in 
T1DM may be limited by severe β-cell deficiency. We previously 
reported that targeted gene delivery of cyclinD2/CDK4/GLP-1 
to the pancreas by ultrasound-targeted microbubble destruction 
(UTMD) resulted in durable islet regeneration and reversal of 
diabetes in streptozotocin-induced rats.14 Using an established 
tether system in baboons,15 we now report results from a pilot 
study to determine if islet regeneration by UTMD gene therapy 
is feasible in a primate with close genetic similarity to humans.
Results
Figures 1 and 2 show the morphology of pancreatic islets 
using triple immunofluorescent staining. Panels A–D show 
staining with anti-insulin (red), anti-glucagon (green), and dapi 
(blue) for the cell nucleus. In the normal baboon, the β cells 
dominate islet structure. Interestingly, many single α cells are 
scattered throughout the pancreas (Fig. 1A) and not just around 
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Both major forms of diabetes mellitus (DM) involve β-cell destruction and dysfunction. New treatment strategies have 
focused on replenishing the deficiency of β-cell mass common to both major forms of diabetes by islet transplantation 
or β-cell regeneration. the pancreas, not the liver, is the ideal organ for islet regeneration, because it is the natural milieu 
for islets. Since islet mass is known to increase during obesity and pregnancy, the concept of stimulating pancreatic islet 
regeneration in vivo is both rational and physiologic. this paper proposes a novel approach in which non-viral gene 
therapy is targeted to pancreatic islets using ultrasound targeted microbubble destruction (UtMD) in a non-human pri-
mate model (NHp), the baboon. treated baboons received a gene cocktail comprised of cyclinD2, CDK, and GLP1, which 
in rats results in robust and durable islet regeneration with normalization of blood glucose, insulin, and C-peptide levels. 
We were able to generate important preliminary data indicating that gene therapy by UtMD can achieve in vivo normal-
ization of the intravenous (IV) glucose tolerance test (IVGtt) curves in StZ hyperglycemic-induced conscious tethered 
baboons. Immunohistochemistry clearly demonstrated evidence of islet regeneration and restoration of β-cell mass.
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islet periphery as demonstrated in rodents. In DsRed-treated 
controls, STZ destroyed almost all β cells, but islet-like struc-
tures containing large clusters of α cells are seen (Fig. 1B). After 
UTMD pBIP3.1-GLP-1/CyclinD2/CDK4 gene therapy at low 
dose, the α cell clusters or islets also contained insulin-producing 
cells or cells co-expressing insulin and glucagon. In high power 
images (Fig. 2), there are cells co-expressing insulin, glucagon, 
and amylase, which is consistent with adult pancreatic progenitor 
cells, and which we have also observed in rodents. In addition, 
there were isolated insulin-producing cells within the pancreatic 
parenchyma, particularly along ducts (Fig. 1C). After UTMD 
pBIP3.1-GLP-1/CyclinD2/CDK4 gene therapy at high dose, 
the appearance of insulin-producing cells within islets was more 
prominent than the ones with low-dose UTMD administration 
(Fig. 1D). Beta-cell fraction (%) was 1.68%, 0.05%, 0.48%, and 
1.05% in normal baboon, DsRed control, low-dose, and high-
dose gene therapy, respectively (Fig. 1E, bottom). This was asso-
ciated with restoration of normal IVGTT in the high-dose gene 
therapy baboon relative to DsRed control baboon (Fig. 3). Also, 
the IVGTT curves clearly show that blood glucose, C-peptide, 
and insulin were recovered in the treated baboon, but not in 
control (Fig. 3). Figure 4 demonstrates that the insulin-pro-
ducing cells stained positive with Ki-67, demonstrating cellular 
proliferation. Transgenic DsRed gene showed evidence of tissue-
specific expression in both α cells and β cells after UTMD gene 
delivery (Fig. 5). RT-PCR also showed that DsRed cDNA was 
abundantly detected in the pancreas and spleen (scanty amounts) 
but not in liver, kidney, skeletal muscle, or heart (Fig. 5, bottom). 
Our previous data demonstrated that this insulin gene promoter 
also worked in α cells; luciferase gene under insulin gene pro-
moter driving had 43% of activities in α cells compared with β 
cells.21 Figure 6 further shows transgenic GLP-1 gene expressed 
in pancreatic β cells in UTMD gene therapy baboons.
Discussion
We used UTMD to direct gene therapy to the pancreas in 
order to reproduce the normal physiologic secretion of insulin 
into the portal circulation, where it acts on the liver to suppress 
hepatic glucose production without causing systemic hyperinsu-
linemia. A combination of CyclinD2, CDK4, and GLP-1 genes 
successfully induced islet regeneration and restoration of β-cell 
mass. Physiologically, this was accom-
panied by improvement of the glucose 
tolerance test in our treated baboons. 
Although this was designed as a pilot 
study to test feasibility and acquire pre-
liminary data, to our knowledge it is 
the first report to demonstrate that gene 
therapy can successfully reverse STZ 
induced-hyperglycemia in a non-human 
primate. Previous studies in rodents 
from our group14 and others22 found 
that α cells are a resource for recovering 
β-cell mass. The present study suggests 
that this occurs in STZ hyperglycemic-
induced conscious tethered baboons and, 
thus, supports the concept that “alpha 
cells beget beta cells”.23,24 It is not clear 
how the origin or formation of pancreatic 
α cell-dominant islets occurs after STZ 
injection. Recently Accili D and his col-
leagues25 reported that adult mature pan-
creatic β cells were dedifferentiated into 
pancreatic progenitor-like cells and then 
proliferated into α cells because of meta-
bolic stress or inflammation. Our data 
from rodents and nonhuman primates 
suggest that gene therapy can re-differ-
entiate these α cells into functioning β 
cells rather than replicating pre-existing 
β cells.
However, further work is needed to 
confirm the mechanism and cellular 
origin underlying islet regeneration in 
primates. It remains possible that the 
effects of STZ influence the results and 
Figure 1. Confocal microscopic images of insulin (red), glucagon (green), and Dapi (blue). (A) Baboon 
ID#11692, normal baboon pancreas; (B) Baboon ID#18175, StZ plus UtMD pBIp3.1-DsRed reporter 
gene; (C) Baboon ID#26104, StZ plus UtMD-pBIp3.1-cyclinD2/CDK4/GLp-1 genes (12 mg of plasmid); 
(D) Baboon ID#20105, StZ plus UtMD-pBIp3.1-cyclinD2/CDK4/GLp-1 genes (20 mg of plasmid); scale 
bar is 120 µm. (E) the lower panel displays the percentage of β-cell area in total pancreatic area (%).
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different findings would be found 
in a naturally occurring form of 
diabetes. Nevertheless, the results of 
this pilot study are encouraging and 
suggest that therapeutic islet regen-
eration is not merely a phenomenon 
that occurs in lower order mammals 
such as rodents.
In conclusion, we were able to 
achieve islet regeneration through 
UTMD gene therapy in STZ hyper-
glycemic-induced conscious teth-
ered baboons, with increase in β-cell 
mass and improvement of plasma 
glucose, insulin, and C-peptide 
without administering viruses. 
Although targeted gene therapy 
has been used experimentally to 
treat diabetes in mice and rats, 
these models are limited by their 
small size, brief life span, potential 
for spontaneous regeneration of the 
pancreas, and differences in main-
tenance of glucose metabolism/islet 
function vs. high-order vertebrates. 
Thus, the present finding of in vivo 
re-differentiation of pre-existing α 
cells into functioning β cells by tar-
geted gene therapy in baboons offers 
strong potential to be translated to 
humans.
Materials and Methods
Animal protocols and UTMD
This study was performed in 
accordance with the recommen-
dations in the Guide for the Care 
and Use of Laboratory Animals of 
the National Institutes of Health. 
The protocol was approved by 
the Institutional Animal Care 
and Use Committees of the Texas 
Biomedical Research Institute and 
Baylor Research Institute (Assurance 
Number: 10–4233). The study 
approval ID is IACUC 1251PC. 
After an overnight fast (~12 h), 
each baboon was sedated with ket-
amine hydrochloride (10 mg/kg 
i.m.) before arrival in the procedure 
room. Endotracheal intubation was 
performed using disposable cuffed 
tubes (6.5–8.0 mm diameter) under 
direct laryngoscopic visualization, 
and all the animals were supported 
Figure 2. the confocal images of triple staining for insulin, amylase, and glucagon (A) Baboon ID#11692, 
normal baboon pancreas; (B) Baboon ID#18175, StZ plus UtMD pBIp3.1-DsRed reporter gene; (C) Baboon 
ID#26104, StZ plus UtMD-pBIp3.1-cyclinD2/CDK4/GLp-1 genes (12 mg of plasmid); (D) Baboon ID#20105, 
StZ plus UtMD-pBIp3.1-cyclinD2/CDK4/GLp-1 genes (20 mg of plasmid); scale bar is 40 µm.
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with 98–99.5% FiO2 by a pressure-con-
trolled ventilator, which was adjusted, as 
necessary, to keep the oxygen saturation 
>95%. The maintenance of anesthesia con-
sisted of an inhaled isofluorane (0.5–1.5%) 
and oxygen mix.
We developed a comprehensive stan-
dardized protocol to induce diabetes in 
baboons using STZ. We utilize 4 baboons in 
this study. One baboon, otherwise healthy 
(ID 11692), scheduled to have euthanasia, 
matched with the weight and age of the ani-
mals chosen for the study, was opportunis-
tically identified to harvest pancreatic tissue 
at the time of necropsy to be considered as 
normal control for pancreas staining. After 
animal selection and acclimation, 3 baboons 
were selected (age = 6–16 y and weight = 
26–34 kg) based on maintenance of food 
intake, general attitude toward study tech-
nical staff, study veterinarian, and comfort 
level with presence of technical staff in bay. 
Animal acclimation to technician presence 
was undertaken prior to the procedure start 
date. All selected animals had an arterial 
and venous tether catheter placed under 
isofluorane anesthesia. A continuous intra-
venous saline 0.9% infusion at a rate of 30 
ml/kg of body weight/day was adminis-
tered 48 h before and after STZ (Zanosar) 
administration to prehydrate the baboons 
and reduce potential nephrotoxic effects. 
All baboons received STZ (administered 
over 5 min) at a dose ranging from 80–150 
mg/kg. In the 72 h after STZ induction, 
frequent blood samples were drawn to 
measure the plasma glucose concentra-
tion, and 50% dextrose was infused at a 
rate designed to maintain the plasma glu-
cose concentration between 80–125 mg/
dl. After 72 h the glucose infusion was 
stopped, and diabetes was confirmed by 
the persistence of fasting hyperglycemia. 
On day 4 following STZ an IVGTT (0.5 
mg/kg of 50% dextrose administered over 
2 min) was performed, with glucose con-
centrations measured every 5–10 min for 
60 min. A fasting plasma glucose level of 
>200 mg/dl in combination with stimu-
lated C-peptide levels of less than 0.4 ng/
ml on the day of the IVGTT was con-
sidered to be indicative of diabetes. All 
animals became diabetic 3 d after STZ 
administration. UTMD was performed 
12 d after STZ in all animals. We admin-
istered a DsRed reporter gene to baboon 
Figure 3. Fasting plasma glucose, insulin, C-peptide concentrations, and plasma glucose concen-
trations of intravenous glucose tolerance tests (IVGtt).
Figure 4. Confocal microscopic images of Ki-67, a marker of proliferation. the high-power images 
show that insulin-producing cells are proliferating in the pancreas of baboon ID#20105(StZ plus 
UtMD-pBIp3.1-cyclinD2/CDK4/GLp-1 genes (20 mg of plasmid); scale bar is 25 µm.
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ID 18175, plasmid DNA containing a 
low-dose (12 mg of plasmids) gene cock-
tail with a combination of cyclin D2, 
CDK4 and GLP-1 to baboon ID 26104, 
and the same gene cocktail to baboon 
ID 20105 with a high-dose of plasmisds 
(20 mg). Euthanasia was performed 21 d 
after UTMD prior to collecting blood to 
measure fasting plasma glucose, insulin, 
C-peptide and performing an IVGTT. 
Pancreas, liver, spleen, kidney, skeletal 
muscle, and heart were harvested for 
pathology and histology studies.
Microbubble solutions were intra-
venously infused over 5 min via pump 
(Genie, Kent Scientific). Three-
milliliters microbubble solution con-
taining a dosage of 12 mg of DsRed 
reporter gene plasmid diluted with 3 
ml phosphate-buffered solution (PBS) 
was administered to baboons ID 18175. 
Three-ml microbubble solution contain-
ing a dosage of 12 mg of plasmid diluted 
with 3 ml phosphate-buffered solution 
(PBS) was administered to baboons ID 
26104. Five-ml microbubble containing 
a dosage of 20 mg of plasmid diluted 
with 5 ml PBS were administered to 
baboon ID 20105. During the infusion, 
ultrasound was directed to the pancreas 
using a commercially available ultra-
sound transducer (S3, Sonos 5500, Philips 
Ultrasound) with slow manual scanning 
back and forth from the tail to the head 
of the pancreas during microbubble perfu-
sion. Ultrasound was applied in ultrahar-
monic mode (transmit 1.3 MHz/receive 3.6 
MHz) at a mechanical index of 1.4. Four 
bursts of ultrasound were triggered to every 
fourth end-systole by electrocardiogram 
using a delay of 45–70 ms after the peak 
of the R wave. We previously demonstrated 
that these settings were optimal for plasmid 
delivery by UTMD using this instrument. 
Bubble destruction was visually apparent 
on ultrasound images of the pancreas of all 
baboons.
Plasmids constructs
Baboon insulin gene promoter con-
struction was performed according to 
Papio hamadryas insulin gene sequences 
information.16 Baboon genomic DNA was 
extracted from Papio hamadryas peripheral 
blood with a QIAamp Blood kit (Qiagen 
Inc). Baboon insulin gene promoter 
primers forward: 5-AGCGCTTAAT 
Figure 5. Upper panels are confocal microscopic images showing transgenic expression of DsRed 
reporter gene in Baboon ID#18175 pancreas. Insulin cells are virtually absent. DsRed colocalizes with 
glucagon in α-cell clusters/islets. Scale bar is 50 µm. Lower panel is Rt-pCR for DsRed cDNA in Baboon 
ID#18175: (A), pancreatic head; (B), pancreatic middle; (C), pancreatic tail; (D) spleen; (E) liver; (F) heart; 
(G) skeletal muscle.
Figure  6. transgenic expression of GLp1 in pancreatic islets, scale bar is 40 µm. (A) Baboon 
ID#11692, normal baboon pancreas; (B) Baboon ID#18175, StZ plus UtMD pBIp3.1-DsRed reporter 
gene; (C) Baboon ID#26104, StZ plus UtMD-pBIp3.1-cyclinD2/CDK4/GLp-1 genes (12 mg of 
plasmid); (D) Baboon ID#20105, StZ plus UtMD-pBIp3.1-cyclinD2/CDK4/GLp-1 genes (20 mg of 
plasmid).
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GTGGAAAGTG GGCC-3, reversed: 5-CTCGAGGGCA 
GAAGGACAGT GACC-3. PCR amplification of baboon 
genomic DNA was performed using forward and reverse prim-
ers containing either Eco47III-XhoI restriction site, respec-
tively. The PCR products were subcloned into the pDsRed1–1 
reporter vector (Clonetech). Human cyclinD217 and CDK418 
cDNA (Addgene Inc) and GLP-1 cDNA with furin cutting sites 
(method of Kim, et al.19) were subcloned to the baboon insu-
lin gene promoter driving vector. Plasmid digestion, subcloning, 
ligation, isolation, and purification were performed by standard 
procedures and sequenced to confirm that no artifactual muta-
tions were present.
RNA isolation and RT-PCR analysis
Total RNA was isolated from 100 mg of harvested pancreas 
using RNA purification kit (Qiagen), according to the manu-
facturer’s instructions and reverse-transcribed using Superscript 
III RT (Invitrogen). RT–PCR analysis was performed on an ABI 
7700 Sequence Detector (Applied Biosystems). CDNA DsRed 
PCR primer sequences were forward: 5′-ATGCGCTTCA 
AGGTGCGCAT; reverse: 5′- AAGGACAGCT TCTTGTA.
Manufacture of plasmid-containing lipid-stabilized 
microbubbles
Lipid-stabilized microbubbles were prepared, as previously 
described, in our laboratory.14 Briefly, 3 ml of liposome solution 
containing DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphatidyl-
choline, Sigma) 2.5 mg/ml; DPPE (1,2-dipalmitoyl-sn-glycero-
3-phosphatidylethanolamine, Sigma) 0.5 mg/ml; and 10% 
glycerol was mixed with 12 mg of plasmid dissolved in 300 µl of 
lipefectamine 2000 (Invitrogen). Aliquots of 1 ml of this phos-
pholipid-plasmid solution were placed in 2.0 ml clear vials; the 
remaining headspace was filled with the perfluoropropane gas 
(Air Products, Inc). Each vial was incubated at 4 °C for 30 min 
and then mechanically shaken for 30 s by a dental amalgamator 
(Vialmix™, Bristol-Myers Squibb Medical Imaging). Three vials 
microbubble solution were transferred into a 10-ml syringe and 
diluted with 3 ml of PBS for one baboon IV perfusion.
Immunohistochemistry
Tissue samples were fixed in 4% paraformaldehyde and 20% 
sucrose overnight at 4 °C, and Cryostat sections 5–8 µm in 
thickness were further fixed with acetone (−20 °C) for 5 min 
and quenched for 5 min with10 mM glycine in PBS. Sections 
were then rinsed in PBS 3 times, and permeabilized with 0.5% 
Triton X-100 in PBS for 10 min. Sections were blocked with 10% 
goat serum at 37 °C for 1 h and washed with PBS 3 times. The 
primary antibodies (guinea pig anti-insulin antibody, 1:100 dilu-
tion; rabbit anti-cyclinD2, rabbit anti-CDK4, rabbit anti-GLP-1, 
rabbit anti-Ki-67 from Abcam Inc, mouse anti-insulin antibody, 
1:500 dilution, mouse anti-glucagon, 1:1000, Sigma; rabbit anti-
glucagon, 1:500, mouse anti-Amylase, 1:50, mouse anti-C-pep-
tide, 1:250, Santa Cruz Biotech) were added and incubated for 
2 h at RT. After washing with PBS 3 times for 5 min, the sec-
ondary antibody (Sigma) anti-guinea pig Ig G-conjugated with 
Texas Red; anti-mouse IgG conjugated with FITC; anti-rabbit 
IgG conjugated with Cy5) (1:500 dilution in block solution) was 
added. Dapi (1:5000 dilution, Invitrogen).
Beta-cell fraction
Beta-cell fraction was evaluated by the method of Terauchi, 
et al.20 Sections of baboon pancreas were immunostained with 
monoclonal guinea pig anti-insulin (1:100 dilution) and a second 
antibody, goat anti-guinea pig IgG-FITC (1:250 dilution). The 
total areas of islet β cells and whole pancreas in slides were mea-
sured using NIH ImageJ software (NIH). The areas of β cells 
and pancreas were determined by counting 6 consecutive slides 
each piece and total 3 pieces (head, middle, and tail) of whole 
baboon pancreas tissue in respective groups.
Data analysis
Data analysis was performed with Statview software (SAS). 
The results are expressed as the mean ± one standard deviation. 
Differences were analyzed by repeated measures ANOVA with 
Fisher post-hoc test and considered significant at P < 0.05.
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